TWST
Twist Bioscience Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+49/100
Last price
167.20
▼ 37.80 (18.44%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
206.00
Prev close
205.00
Day high
219.71
Day low
164.49
Volume
8.55M
Market cap
$11.07B
P/E (TTM)
—
52W range
23.30 – 219.71
Day trading desk
Gap from prior close
+9.19%
Prior close 188.67
VWAP
174.51
-4.19% from price
Relative volume
8.31×
Unusually busy
Session range
33.57%
164.49 – 219.71
Position in range
5%
Near session low
ATR (14D)
13.49
8.07% of price
Prior day high
198.10
PDH
Prior day low
183.39
PDL
Bid / ask spread
—
Quote not published
Session volume
15.21M
Avg 1.83M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+14.14%
+12.2%
1M
+59.27%
+58.1%
3M
+125.20%
+120.7%
6M
+300.55%
+282.4%
YTD
+546.28%
+532.0%
1Y
+568.19%
+551.8%
3Y
+897.08%
+814.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on TWST open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
-521.83K
Net selling
Buy transactions
11
497.83K shares
Sell transactions
71
1.02M shares
Net transactions
+82
Buys less sells
Sell : buy shares
2.0 : 1
Mixed
Insider-held shares
476.58K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Oct 2, 26 | FINN PATRICK JOHN President |
SELL | 25.71K | $4.86M | Direct |
| Oct 2, 26 | CHO DENNIS Officer |
SELL | 9.51K | $1.80M | Direct |
| Oct 2, 26 | LEPROUST EMILY M Chief Executive Officer |
SELL | 46.39K | $8.77M | Direct |
| Oct 2, 26 | GREEN PAULA Officer |
SELL | 10.09K | $1.91M | Direct |
| Oct 2, 26 | WERNER ROBERT F. Officer |
SELL | 1.48K | $279.93K | Direct |
| Oct 2, 26 | LAPONIS ADAM Chief Financial Officer |
SELL | 8.06K | $1.52M | Direct |
| Sep 21, 26 | CHO DENNIS Officer |
SELL | 348 | $57.59K | Direct |
| Sep 21, 26 | LEPROUST EMILY M Chief Executive Officer |
SELL | 1.69K | $279.18K | Direct |
| Sep 21, 26 | GREEN PAULA Officer |
SELL | 294 | $48.65K | Direct |
| Sep 17, 26 | LEPROUST EMILY M Chief Executive Officer |
CONVERSION | 208.71K | $4.22M | Direct |
| Sep 17, 26 | LEPROUST EMILY M Chief Executive Officer |
SELL | 356.55K | $56.33M | Direct |
| Sep 8, 26 | CHO DENNIS Officer |
SELL | 412 | $50.52K | Direct |
| Sep 8, 26 | LEPROUST EMILY M Chief Executive Officer |
SELL | 2.30K | $282.28K | Direct |
| Sep 8, 26 | GREEN PAULA Officer |
SELL | 907 | $111.22K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CHAN NELSON C |
Director | 33.25K | Stock Award(Grant) |
CHESS ROBERT BRUCE |
Director | 63.61K | Conversion of Exercise of derivative security |
CHO DENNIS |
Officer | 63.79K | Sale |
CRANDELL KEITH L. |
Director | 103.62K | Stock Award(Grant) |
FINN PATRICK JOHN |
President | 185.09K | Sale |
GREEN PAULA |
Officer | 106.63K | Sale |
LAPONIS ADAM |
Chief Financial Officer | 100.58K | Sale |
LEPROUST EMILY M |
Chief Executive Officer | 567.31K | Sale |
RAGUSA ROBERT P. |
Director | 28.98K | Stock Award(Grant) |
WERNER ROBERT F. |
Officer | 42.92K | Sale |
Fundamentals
Market cap$11.07B
Enterprise value$10.41B
Revenue (TTM)$431.80M
Gross profit$224.38M
EBITDA$-115.28M
Net income$-136.72M
EPS (TTM)$-2.42
Free cash flow$-64.82M
Total cash$166.84M
Total debt$108.59M
Book value / share$7.11
Shares outstanding66.30M
Float61.97M
Short % of float23.79%
Dividend yield0.00%
Beta (5Y)2.19
Valuation & profitability ratios
Trailing P/E—
Forward P/E-222.15
PEG ratio—
Price / sales—
Price / book23.48
EV / revenue24.11
EV / EBITDA-90.32
Gross margin51.96%
Operating margin-30.65%
Profit margin-31.66%
Return on equity-29.59%
Return on assets-13.09%
Debt / equity24.36
Current ratio2.67
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $376.57M | $312.97M | $245.11M | $203.56M | +20.3% |
| Operating revenue | $376.57M | $312.97M | $245.11M | $203.56M | +20.3% |
| Cost of revenue | $185.57M | $179.63M | $155.38M | $119.33M | +3.3% |
| Gross profit | $191.00M | $133.35M | $89.73M | $84.23M | +43.2% |
| Research & development | $80.28M | $90.85M | $106.89M | $120.31M | -11.6% |
| Selling, general & admin | $246.98M | $218.40M | $189.74M | $212.95M | +13.1% |
| Total operating expense | $327.26M | $309.25M | $296.63M | $333.26M | +5.8% |
| Operating income | -$136.26M | -$175.90M | -$206.90M | -$249.02M | +22.5% |
| Net interest income | $11.36M | $15.34M | $14.37M | $2.98M | -25.9% |
| Pre-tax income | -$76.95M | -$208.17M | -$203.47M | -$228.27M | +63.0% |
| Tax provision | $719.00K | $560.00K | $1.15M | -$10.41M | +28.4% |
| Net income | -$77.67M | -$208.73M | -$204.62M | -$217.86M | +62.8% |
| Net income to common | -$77.67M | -$208.73M | -$204.62M | -$217.86M | +62.8% |
| Basic EPS | -1.30 | -3.60 | -3.60 | -4.04 | +63.9% |
| Diluted EPS | -1.30 | -3.60 | -3.60 | -4.04 | +63.9% |
| EBIT | -$136.26M | -$175.90M | -$206.90M | -$228.19M | +22.5% |
| EBITDA | -$111.41M | -$144.47M | -$177.59M | -$211.68M | +22.9% |
| Basic shares | 59.81M | 58.02M | 56.88M | 53.88M | +3.1% |
| Diluted shares | 59.81M | 58.02M | 56.88M | 53.88M | +3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $183.05M | $226.32M | $286.47M | $378.69M | -19.1% |
| Cash & short-term investments | $232.43M | $276.40M | $336.41M | $504.97M | -15.9% |
| Accounts receivable | $57.02M | $34.90M | $44.06M | $40.29M | +63.4% |
| Inventory | $28.31M | $24.08M | $32.06M | $39.31M | +17.6% |
| Total current assets | $332.97M | $346.78M | $424.26M | $596.48M | -4.0% |
| Property, plant & equipment | $151.66M | $161.35M | $203.36M | $214.39M | -6.0% |
| Goodwill & intangibles | $95.62M | $100.29M | $140.29M | $145.55M | -4.7% |
| Total assets | $641.86M | $614.32M | $776.40M | $961.38M | +4.5% |
| Total current liabilities | $91.41M | $71.01M | $73.32M | $90.66M | +28.7% |
| Total debt | $75.57M | $85.03M | $94.07M | $94.91M | -11.1% |
| Total liabilities | $168.90M | $141.63M | $152.97M | $171.99M | +19.3% |
| Retained earnings | -$1.32B | -$1.24B | -$1.03B | -$828.42M | -6.3% |
| Shareholder equity | $472.96M | $472.69M | $623.43M | $789.38M | +0.1% |
| Working capital | $241.56M | $275.77M | $350.93M | $505.82M | -12.4% |
| Net tangible assets | $377.34M | $372.40M | $483.14M | $643.84M | +1.3% |
| Shares issued | 60.63M | 58.88M | 57.56M | 56.52M | +3.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$77.67M | -$208.73M | -$204.62M | -$217.86M | +62.8% |
| Depreciation & amortisation | $24.85M | $31.43M | $29.31M | $16.51M | -20.9% |
| Stock-based compensation | $64.46M | $50.92M | $30.28M | $79.66M | +26.6% |
| Change in working capital | -$12.61M | $15.41M | -$1.01M | -$5.36M | -181.8% |
| Operating cash flow | -$47.63M | -$64.09M | -$142.47M | -$124.39M | +25.7% |
| Capital expenditure | -$28.00M | -$5.08M | -$27.78M | -$101.86M | -451.7% |
| Investing cash flow | -$24.76M | -$3.07M | $50.61M | -$232.93M | -706.3% |
| Share buybacks | -$16.00K | -$3.98M | -$4.41M | -$7.75M | +99.6% |
| Financing cash flow | $28.54M | $6.89M | $911.00K | $270.53M | +314.2% |
| Free cash flow | -$75.63M | -$69.17M | -$170.25M | -$226.24M | -9.3% |
| End cash position | $185.43M | $229.13M | $289.28M | $380.26M | -19.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $118.38M | $110.72M | $103.70M | $99.01M | $96.06M | +6.9% |
| Operating revenue | $118.38M | $110.72M | $103.70M | $99.01M | $96.06M | +6.9% |
| Cost of revenue | $55.92M | $53.59M | $49.73M | $48.17M | $44.76M | +4.3% |
| Gross profit | $62.45M | $57.12M | $53.97M | $50.84M | $51.30M | +9.3% |
| Research & development | $18.02M | $19.70M | $17.13M | $17.01M | $18.05M | -8.5% |
| Selling, general & admin | $80.71M | $76.08M | $69.94M | $63.76M | $63.37M | +6.1% |
| Total operating expense | $98.73M | $95.78M | $87.07M | $80.77M | $81.42M | +3.1% |
| Operating income | -$36.28M | -$38.66M | -$33.10M | -$29.93M | -$30.12M | +6.2% |
| Net interest income | $1.50M | $1.71M | $2.17M | $2.63M | $2.69M | -12.3% |
| Pre-tax income | -$34.74M | -$43.98M | -$30.25M | -$26.88M | $20.58M | +21.0% |
| Tax provision | $311.00K | $43.00K | $253.00K | $257.00K | $191.00K | +623.3% |
| Net income | -$35.05M | -$44.02M | -$30.51M | -$27.14M | $20.39M | +20.4% |
| Net income to common | -$35.05M | -$44.02M | -$30.51M | -$27.14M | $20.39M | +20.4% |
| Basic EPS | -0.56 | -0.71 | -0.50 | -0.45 | 0.34 | +21.1% |
| Diluted EPS | -0.56 | -0.71 | -0.50 | -0.45 | 0.33 | +21.1% |
| EBIT | -$36.28M | -$38.66M | -$33.10M | -$29.93M | -$30.12M | +6.2% |
| EBITDA | -$29.50M | -$32.24M | -$26.91M | -$23.93M | -$24.05M | +8.5% |
| Basic shares | 62.40M | 61.70M | 61.08M | 60.42M | 59.99M | +1.1% |
| Diluted shares | 62.40M | 61.70M | 61.08M | 60.42M | 61.16M | +1.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $117.44M | $122.67M | $148.59M | $183.05M | $201.37M | -4.3% |
| Cash & short-term investments | $166.84M | $171.67M | $197.95M | $232.43M | $250.80M | -2.8% |
| Accounts receivable | $65.06M | $64.15M | $50.06M | $57.02M | $49.85M | +1.4% |
| Inventory | $35.16M | $33.52M | $32.92M | $28.31M | $25.94M | +4.9% |
| Total current assets | $321.30M | $323.44M | $303.88M | $332.97M | $339.78M | -0.7% |
| Property, plant & equipment | $180.62M | $181.88M | $177.38M | $151.66M | $147.20M | -0.7% |
| Goodwill & intangibles | $94.92M | $95.19M | $95.36M | $95.62M | $95.88M | -0.3% |
| Total assets | $672.44M | $676.21M | $638.09M | $641.86M | $643.61M | -0.6% |
| Total current liabilities | $120.25M | $119.98M | $80.44M | $91.41M | $87.07M | +0.2% |
| Total debt | $93.59M | $95.84M | $98.05M | $75.57M | $78.15M | -2.3% |
| Total liabilities | $226.70M | $221.12M | $181.99M | $168.90M | $165.41M | +2.5% |
| Retained earnings | -$1.43B | -$1.39B | -$1.35B | -$1.32B | -$1.29B | -2.5% |
| Shareholder equity | $445.74M | $455.09M | $456.10M | $472.96M | $478.20M | -2.1% |
| Working capital | $201.04M | $203.46M | $223.44M | $241.56M | $252.71M | -1.2% |
| Net tangible assets | $350.81M | $359.90M | $360.74M | $377.34M | $382.31M | -2.5% |
| Shares issued | 62.67M | 62.15M | 61.27M | 60.63M | 60.17M | +0.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$35.05M | -$44.02M | -$30.51M | -$27.14M | $20.39M | +20.4% |
| Depreciation & amortisation | $6.78M | $6.41M | $6.19M | $6.00M | $6.07M | +5.7% |
| Stock-based compensation | $18.18M | $18.94M | $13.27M | $16.08M | $16.06M | -4.0% |
| Change in working capital | $11.05M | $1.61M | -$13.44M | -$6.98M | $3.78M | +586.4% |
| Operating cash flow | $1.11M | -$17.56M | -$24.81M | -$11.81M | -$1.40M | +106.4% |
| Capital expenditure | -$9.76M | -$7.99M | -$9.97M | -$12.43M | -$9.16M | -22.2% |
| Investing cash flow | -$10.20M | -$12.71M | -$9.93M | -$12.40M | -$9.40M | +19.7% |
| Share buybacks | -$6.00K | -$8.00K | -$2.00K | -$2.00K | -$3.00K | +25.0% |
| Financing cash flow | $3.79M | $4.14M | $298.00K | $5.57M | $1.83M | -8.5% |
| Free cash flow | -$8.65M | -$25.55M | -$34.79M | -$24.24M | -$10.56M | +66.1% |
| End cash position | $119.57M | $124.85M | $150.99M | $185.43M | $203.91M | -4.2% |
Options analytics
Put / call volume
0.65
Call-heavy session
Put / call open interest
1.55
Positioning, not flow
Max pain
170.00
+1.8% from spot
ATM implied vol
87.0%
Nearest strike to spot
Skew (10% OTM)
-6.9%
Calls bid over puts
Call volume
6.54K
Contracts, this expiry
Put volume
4.28K
Contracts, this expiry
Heaviest call OI
200.00
446 contracts
Heaviest put OI
170.00
1.11K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.28 | -0.56 | -98.5% |
| Mar 2026 | -0.53 | -0.60 | -12.6% |
| Dec 2025 | -0.52 | -0.50 | +3.9% |
| Sep 2025 | -0.50 | -0.45 | +10.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.15 | 3 | $123.57M | +24.8% |
| Next quarter | -0.14 | 3 | $125.83M | +21.3% |
| Current year | -0.96 | 4 | $456.35M | +21.2% |
| Next year | -0.73 | 5 | $541.25M | +18.6% |
Analyst targets & ownership
Mean target$133.75
High target$215.00
Low target$36.00
Implied upside-20.01%
Analyst count12
ConsensusBUY
Strong buy / Buy2 / 7
Hold3
Sell / Strong sell1 / 0
Held by insiders0.76%
Held by institutions117.07%
Institutions holding464
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
183.07
-8.67% from price
SMA 20
162.13
+26.44% from price
SMA 50
138.01
+48.54% from price
SMA 100
108.88
+53.56% from price
SMA 200
77.93
+163.06% from price
EMA 12
180.00
-7.11% from price
EMA 26
162.60
+2.83% from price
EMA 50
143.37
+16.62% from price
RSI (14)
76.0
Overbought
MACD (12,26,9)
17.41
Hist 2.91
ATR (14)
13.49
6.58% of price
Realised vol 30D
74.8%
Annualised
Bollinger upper
212.58
20, 2σ
Bollinger lower
111.68
20, 2σ
50 / 200 cross
Golden
138.01 vs 77.93
Trend bias
Above 200
+163.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.08
Less volatile than market
Correlation to SPY
-0.01
Largely independent
Realised vol 30D
74.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-25.5%
Peak to trough
Max drawdown 5Y
-91.5%
Peak to trough
ATR 14
13.49
6.58% of price
Beta (reported)
2.19
5Y monthly, from filing
Short interest
Shares short
12.51M
Prior 14.11M
Change vs prior
-11.4%
Shorts covering
% of float
23.79%
Heavily shorted
% of shares out
18.86%
Against total outstanding
Days to cover
7.7
Crowded exit
Float
61.97M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Sep 29, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Sep 18, 26 | BWS Financial | MAINTAINED | Sell | Sell |
| Sep 17, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Sep 9, 26 | BWS Financial | INITIATED | — | Sell |
| Sep 9, 26 | UBS | INITIATED | — | Neutral |
| Aug 5, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 4, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Jul 14, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Jul 6, 26 | Evercore ISI Group | DOWNGRADE | Outperform | In-Line |
| Jun 29, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jun 24, 26 | Barclays | MAINTAINED | Overweight | Overweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-05
Periodic Financial Reports
10-Q · 2026-08-03
Offering Registrations
S-3ASR · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-04
Periodic Financial Reports
10-Q/A · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2026-02-17
Corporate Changes & Voting Matters
8-K · 2026-02-06
Corporate Changes & Voting Matters
8-K · 2026-02-02
Headlines
NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue Beat
TIKR · 8h ago
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Stocktwits · 13h ago
Cathie Wood’s ARKG Is Crushing Her Other ETFs: 2 Biotech Bets Have Surged Nearly 6X This Year
Stocktwits · 2d ago
Twist Bioscience (TWST) Stock Fair Value Edges Higher As Analysts Split On AI Upside
Simply Wall St. · 5d ago
Twist Bioscience (TWST) Stock Could Be Reasonable On Its 9x Three Year Run
Simply Wall St. · 5d ago
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment
CNW Group · 5d ago
Foundayo’s Early Growth Is Raising Lilly (LLY)’s Revenue Expectations. But Can It Outrun Pricing Pressure?
Insider Monkey · 10d ago
What Needs To Be True To Buy Twist Bioscience Stock Now?
Trefis · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.